Zoledronic Acid in Cystic Fibrosis
Launched by PAPWORTH HOSPITAL NHS FOUNDATION TRUST · Oct 4, 2012
Trial Information
Current as of July 21, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of cystic fibrosis
- • Aged at least 18 years
- • Bone mineral density score of -1.5 or less at lumbar spine or total hip
- • Able to give informed consent
- Exclusion Criteria:
- • Previous solid organ transplant
- • on solid organ transplant waiting list
- • Long trem oral glucocorticosteroids
- • CRP \>20mg on day of randomisation
- • Hypocalcaemia
- • Poor dental hygiene
About Papworth Hospital Nhs Foundation Trust
Papworth Hospital NHS Foundation Trust is a leading healthcare institution in the United Kingdom, renowned for its specialized services in cardiothoracic medicine and surgery. As a prominent clinical trial sponsor, the Trust is dedicated to advancing medical research and improving patient outcomes through innovative trials and studies. With a commitment to excellence in patient care, Papworth Hospital collaborates with various stakeholders, including academic institutions and pharmaceutical companies, to facilitate cutting-edge research that addresses critical health challenges. The Trust's experienced team of clinicians and researchers is focused on delivering high-quality evidence that contributes to the advancement of healthcare practices and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cambridge, Cambridgeshire, United Kingdom
Patients applied
Trial Officials
Charles Dr Haworth, FRCP
Principal Investigator
Papworth Hospital NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials